GSK Logo


Are you a Healthcare Professional? Visit the Healthcare Professional website.



Product overview

What is HER2-positive metastatic breast cancer?

Breast cancer with lots of HER2 receptors is called HER2 positive breast cancer. HER2 receptors can signal for the cancer to grow. Advanced and metastatic are the names used when cancer has spread beyond the original cancer site.

What is Tyverb?

Tyverb is a tablet medicine. It can slow down or stop the growth of advanced or metastatic HER2 positive breast cancers in some patients.

How does Tyverb work?

Tyverb helps to block the HER2 receptors from signaling the cancer to grow.

What other drugs are taken with Tyverb?

  • Tyverb is often prescribed with another medicine called capecitabine (also known as Xeloda®)
  • Tyverb can be prescribed with an aromatase inhibitor such as letrozole (also known as Femara®), anastrozole (also known as Arimidex®) or exemestane (also known as Aromasin®). This combination is used for patients whose breast cancer has a lot of Hormone Receptors (HR positive).
  • Tyverb can also be prescribed with another anti-cancer medicine, trastuzumab (also known as Herceptin®). This combination is used for patients whose breast cancer has very few Hormone Receptors (HR negative).

Tyverb is only prescribed by a doctor after a number of thorough checks and is not suitable for all patients.

For further information on Tyverb please see:

additional monitoring symbol

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at By reporting side effects you can help provide more information on the safety of this medicine.

Tyverb is a trademark of the GlaxoSmithKline group of companies.

Rate the usefulness of this page

Rollover stars, click to select, then press submit.

C.X: Last updated 01 June 2014: UK/LPD/0033/14

Links & Resources

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.